Therapeutic Expertise

TRN can provide advisers with in-depth expertise in key therapeutic areas including Cardiovascular, Metabolic disease, Inflammation, Anti-infectives, Neuroscience and Oncology.

The team’s experience spans small molecules (including oligonucleotides) and biologics (peptides, mabs and rProteins) across multiple phases (target identification, lead identification, lead optimisation, pre-clinical and clinical development).

The team’s goal is to increase the speed and efficiency for you in taking your idea, concept or asset to the market. We will partner with you to discuss your needs and develop and execute the best strategic plan to control risk, maintain disciplined investment, and provide you with the best chance of success.

Our team can help you with selecting appropriate targets, then developing a clear target profile that will be aligned to a potential patient group, thus increasing the chances of success. We can help you design the key biology experiments, both in vitro and in vivo, that will be needed to determine which compounds have the profile needed for clinical activity.

With our network of CRO partners, we can design and deliver innovative studies to move your projects forward effectively and efficiently.

Whether you are a large pharmaceutical company looking to efficiently outsource the advancement of your candidate drug to first time in man, or a university technology transfer group looking to maximise the medical and financial benefit of discoveries from academic scientists, we can help you generate efficiently and effectively the right data for key decision points.

 

 

HOW WE WORK

A TRN team member will be selected as your primary partner throughout the project and act as your key point of contact. This TRN team member will coordinate the work of our specialists.

We can partner with you to deliver full data packages as part of a project team or offer consultancy services as needed to deliver any or all of the following:

  • Target Validation studies
  • Assay design and development
  • Screening cascade and triage consultancy and implementation
  • Hit-to-lead and candidate profiling
  • Pre-clinical packages to meet regulatory requirements.
  • Updates to Investigator Brochures and INDs.
  • Dose setting
  • Data analysis planning
  • Report writing
  • Support representation to regulatory authorities including Advisory Committees, meetings to seek scientific advice and other ad hoc meetings.
  • Critique and advice on the strategy to prosecute for a given hypothesis, in either discovery or early clinical phases, to tailor approach to specific patient group
  • Critical review of data and plans to ensure project will meet goals
  • Critique of projects aimed at identifying new drug targets
  • Guidance on experimental design (biochemical, cell culture, in vivo, ex vivo, pre-clinical or clinical PK/PD) to ensure agents have best chance to achieve clinical activity